When selecting subjects for a Phase IV study, which factors should be considered?

• A. Stage of development and indication to be studied
• B. Prior non-clinical and clinical knowledge
• C. Stage of development and level of safety concern
• D. All of the above

Answer: (D)

Phase IV studies rely on what’s already known about the product and aim to gather data in real-world use, so subject selection must reflect multiple interconnected factors. The stage of development tells you how much data exist and how much you still need to confirm about safety and use; this influences who should be enrolled to fill knowledge gaps without exposing people to unanticipated risks. The indication to be studied matters because different uses can carry different risk–benefit profiles, so you tailor inclusion to the specific population and outcome of interest. Prior non-clinical and clinical knowledge provides a roadmap of potential risks and the kinds of safety monitoring that are necessary, shaping who is eligible and what safety checks are essential. The level of safety concern directly affects the stringency of eligibility criteria, the intensity of monitoring, and risk mitigation strategies you must implement. Combining these factors helps protect participants while generating useful information about real-world safety and effectiveness. In short, all of these considerations are relevant and should be addressed in selecting subjects for a Phase IV study.